PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Plain-language summary
This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
PD-1 antibody (DRUG): Administration of PD-1 mAb will start on Day 1 of radiotherapy (C1D1) at a dose of 200 mg via intravenous infusion over 30 minutes or longer, once every 3 weeks, cycle 1 - cycle 6 | radiotherapy (RADIATION): Concurrent standard involved-site radiotherapy (ISRT) | Chidamide (DRUG): The dosage of chidamide will follow a dose-escalation design: 20 mg twice weekly (biw) in the first stage, then escalated to 30 mg biw, using the Bayesian Optimal Interval (BOIN) design to determine the recommended dose, followed by dose expansion in the second stage, every 3 weeks, cycle 4 - cycle 6. | golidocitinib (DRUG): Golidocitinib will be administered at a dose of 150 mg once daily (qd), every 3 weeks, cycle 4 - cycle 6.
- Drugs / treatments
- PD-1 antibody, radiotherapy, Chidamide, golidocitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details